| Catalog No. | HS856106 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa-[scFv]2 |
|---|
| Expression system |
Mammalian Cells |
| Species |
Human |
| Clonality |
Monoclonal |
| Target |
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| Endotoxin level |
Please contact with the lab for this information. |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q16552 & Q9Y275 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names | Bispecific, LY 3090106, LY-3090106, LY3090106, 1849636-24-3 |
|---|
| Background | Tibulizumab (LY-3090106) is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
|
|---|
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
